Hosted on MSN5mon
Novo Nordisk (NVO) Registers a Bigger Fall Than the Market: Important Facts to Note
Novo Nordisk (NVO) closed the most recent trading day at $117.81, moving -1.64% from the previous trading session. The stock trailed the S&P 500, which registered a daily loss of 0.76%.
Novo Nordisk: Not As Bullish As Many
Novo Nordisk shares have dropped ~50% since June 2024 due to poor trial results and other negative catalysts. See why I rate ...
STAT29d
Novo Nordisk shares drop after next-gen obesity drug disappoints in diabetes trial
Shares of Novo Nordisk dropped Monday after the company ... meaning it allowed patients to modify their dosing rather than stay on the highest dose. By the end of the study, 62% of patients ...
Nasdaq18d
Why Novo Nordisk (NVO) Dipped More Than Broader Market Today
In the latest trading session, Novo Nordisk (NVO) closed at $78.79 ... It's only 1/9,000th the size of NVIDIA which skyrocketed more than +800% since we recommended it. NVIDIA is still strong ...
MedCity News28d
Novo Nordisk’s Next-Gen Obesity Drug Disappoints Again With Lower Than Expected Weight Loss
CagriSema is one of a growing number of drugs being developed to show that hitting two targets is better than one for achieving weight loss. It’s important for Novo Nordisk, which has several ...
Reuters29d
Data on new Novo Nordisk obesity drug disappoints in trial, shares drop
LONDON/COPENHAGEN, March 10 (Reuters) - Novo Nordisk on Monday revealed weaker-than-expected data from a second late-stage trial of its obesity drug candidate CagriSema, knocking shares and ...